Chuck Grassley actually said...

"I think they harm drug competition."

"We should be doing all we can to see that the American consumer has access to lower-priced drugs."

"The reality is that these deals between brand-name and generic pharmaceutical companies delay the entry of generic medicines into the marketplace."

"In my opinion, they only end up keeping drug costs artificially high for consumers and the taxpaying public."